Home › Research › Drug development
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity
Kotecha P, Lee YA, Presti MF, Guo Y, Bian J, Guo J.. medRxiv, 2025-12-02
Topic: Gut, metabolism and diet
Plain-language summary
Introduction Parkinsonism encompasses neurodegenerative disorders characterized by rigidity, tremor, and bradykinesia, with Parkinson’s disease (PD) accounting for most cases. Emerging evidence suggests that metabolic dysfunction, including insulin resistance and neuroinflammation, may contribute to PD pathogenesis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for type 2 diabetes (T2D) and obesity, demonstrate neuroprotective effects in preclinical PD models. However, real-world evidence in individuals without T2D is limited. This study evaluated whether GLP-1RA use among adults with obesity or overweight is associated with the risk of PD and Parkinsonian disorders. Methods We conducted a retrospective cohort study using 2014-2024 electronic health record data from the OneFlorida+ Network. Adults with obesity (BMI ≥30 kg/m 2 ), overweight (BMI 25-29.9 kg/m 2 ) with a weight-related comorbidity, or an obesity diagnosis were eligible. Exclusions included age <50 years, <30 days of follow-up, baseline PD or Parkinsonism, anti-Parkinson medication use, or T2D. GLP-1RA users were matched 1:1 to non-users using time-conditional propensity scores. Outcomes were a composite of (1) PD/Parkinsonism and (2) any Parkinsonian-related disorder, including PD, Parkinsonism, Lewy body dementias, and multiple system atrophy. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Results The matched cohort included 11,683 GLP-1RA users and 11,683 non-users with balanced characteristics and a median follow-up of 286 days. GLP-1RA use was not associated with reduced risk of PD or Parkinsonism (22 vs. 33 events; HR 0.70, 95% CI 0.41-1.22) or any Parkinsonian-related disorder (98 vs. 108 events; HR 0.96, 95% CI 0.73-1.27). Findings were consistent in subgroup and sensitivity analyses. Conclusion Among adults with obesity or overweight with a weight related condition, there was no difference in the risk of PD or Parkinsonian disorders between GLP-1 RA users and non-users. Longer follow-up and clinical trials are needed to clarify potential neuroprotective effects across populations.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kotecha, P., Lee, Y. A., Presti, M. F., Guo, Y., Bian, J., & Guo, J. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity. medRxiv. https://doi.org/10.64898/2025.11.24.25340763
Vancouver
Kotecha P, Lee YA, Presti MF, Guo Y, Bian J, Guo J. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity. medRxiv. 2025. doi:10.64898/2025.11.24.25340763.
BibTeX
@article{kotecha2025-0839901b,
author = {Kotecha, P. and Lee, Y. A. and Presti, M. F. and Guo, Y. and Bian, J. and Guo, J.},
title = {{Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity}},
journal = {medRxiv},
year = {2025},
doi = {10.64898/2025.11.24.25340763},
url = {https://doi.org/10.64898/2025.11.24.25340763}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Emerging evidence suggests that metabolic dysfunction, including insulin resistance and neuroinflammation, may contribute to PD pathogenesis.
- This study evaluated whether GLP-1RA use among adults with obesity or overweight is associated with the risk of PD and Parkinsonian disorders.
- Results The matched cohort included 11,683 GLP-1RA users and 11,683 non-users with balanced characteristics and a median follow-up of 286 days.
- GLP-1RA use was not associated with reduced risk of PD or Parkinsonism (22 vs. 33 events; HR 0.70, 95% CI 0.41-1.22) or any Parkinsonian-related disorder (98 vs. 108 events; HR 0.96, 95% CI 0.73-1.27).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants11,683
- Effect sizeHR 0.70; HR 0.96
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 50 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 31 of the 62 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 11,683 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 31 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 31 of the 62 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “peptide-1”
285 studies in the library carry the topic tag “peptide-1”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.